Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

11.1%

3 terminated/withdrawn out of 27 trials

Success Rate

88.5%

+2.0% vs industry average

Late-Stage Pipeline

37%

10 trials in Phase 3/4

Results Transparency

48%

11 of 23 completed trials have results

Key Signals

11 with results

Enrollment Performance

Analytics

Phase 3

10(45.5%)

Phase 1

6(27.3%)

Phase 2

6(27.3%)

22Total

Phase 3(10)

Phase 1(6)

Phase 2(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials

NCT03960359Active Not Recruiting

Inflammatory and Immune Profiles During a Severe Exacerbation in Preschool Asthmatic Children (<5 Years)

Role: collaborator

NCT05668390Phase 3Completed

Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma

Role: lead

NCT01199133Phase 3Terminated

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children

Role: lead

NCT01527188Phase 2Completed

Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model

Role: lead

NCT01919554Phase 1Completed

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents

Role: lead

NCT06574061Completed

Evaluation of the Benefits of Sublingual AIT (PRACTIS)

Role: lead

NCT02443805Phase 3Completed

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

Role: lead

NCT04004351Completed

Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma

Role: lead

NCT02295969Completed

Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis

Role: lead

NCT00409409Phase 3Completed

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Role: lead

NCT00418379Phase 3Completed

Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

Role: lead

NCT00803244Phase 3Completed

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Role: lead

NCT00367640Phase 2Completed

Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

Role: lead

NCT00619827Phase 1Completed

Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

Role: lead

NCT00674700Phase 2Completed

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis

Role: lead

NCT00955825Phase 3Completed

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Role: lead

NCT02041624Terminated

International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis

Role: lead

NCT01930461Phase 2Completed

Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma

Role: lead

NCT01608243Phase 1Completed

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

Role: lead

NCT01964768Phase 3Completed

Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing

Role: lead